Alto Neuroscience (ANRO) Liabilities and Shareholders Equity (2023 - 2026)

Alto Neuroscience has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $276.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 60.7% year-over-year to $276.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $765.8 million (up 3.71% YoY) and the FY2025 annual result came in at $184.7 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity climbed to $276.3 million in Q1 2026 per ANRO's latest filing, from $184.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $276.3 million in Q1 2026 and troughed at $86.6 million in Q4 2023.
• A 4-year average of $180.1 million and a median of $181.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 104.95% in 2024, then retreated 23.28% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $86.6 million in 2023, then surged by 104.95% to $177.5 million in 2024, then gained by 4.03% to $184.7 million in 2025, then soared by 49.58% to $276.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $276.3 million, $184.7 million, and $147.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.